Published in BMJ on June 02, 1990
Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med (2012) 10.93
Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol (2008) 5.61
Illness trajectories and palliative care. BMJ (2005) 5.19
Associations between palliative chemotherapy and adult cancer patients' end of life care and place of death: prospective cohort study. BMJ (2014) 3.90
Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment. BMJ (1994) 3.52
The role of chemotherapy at the end of life: "when is enough, enough?". JAMA (2008) 3.31
Malignant cerebral glioma--II: Perspectives of patients and relatives on the value of radiotherapy. BMJ (1996) 2.95
Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ (1998) 2.66
How do patients' treatment preferences compare with those of clinicians? Qual Health Care (2001) 2.62
Toward a theoretical model of quality-of-life appraisal: Implications of findings from studies of response shift. Health Qual Life Outcomes (2004) 2.33
Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncol (2015) 2.29
Prospective study of health status preferences and changes in preferences over time in older adults. Arch Intern Med (2006) 2.18
Parents' views of cancer-directed therapy for children with no realistic chance for cure. J Clin Oncol (2008) 2.12
Planning for a good death: responding to unexpected events. BMJ (2003) 2.10
Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer (2006) 1.99
Recruitment of patients with lung cancer into a randomised clinical trial: experience at two centres. On behalf of the Big Lung Trial Steering Committee. Thorax (2000) 1.84
Understanding provision of chemotherapy to patients with end stage cancer: qualitative interview study. BMJ (2011) 1.77
Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy. Br J Cancer (2005) 1.71
Quality of life: philosophical question or clinical reality? BMJ (1992) 1.68
Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol (2007) 1.55
Eliciting patients' preferences for adjuvant chemotherapy in breast cancer: development and validation of a bedside decision-making instrument in a French Regional Cancer Centre. Health Expect (2000) 1.52
Chemotherapy of advanced breast cancer: outcome and prognostic factors. Br J Cancer (1993) 1.45
Time-Limited Trials of Intensive Care for Critically Ill Patients With Cancer: How Long Is Long Enough? JAMA Oncol (2016) 1.45
New treatments for advanced cancer: an approach to prioritization. Br J Cancer (2000) 1.41
What are the information priorities for cancer patients involved in treatment decisions? An experienced surrogate study in Hodgkin's disease. Br J Cancer (1996) 1.37
Patients' preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwhile? Br J Cancer (2001) 1.34
Older breast cancer survivors: geriatric assessment domains are associated with poor tolerance of treatment adverse effects and predict mortality over 7 years of follow-up. J Clin Oncol (2009) 1.31
Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians. J Clin Oncol (2010) 1.27
Second opinions for patients with cancer. BMJ (1995) 1.23
Physicians' evaluations of patients' decisions to refuse oncological treatment. J Med Ethics (2005) 1.22
Emotional dimensions of chronic disease. West J Med (2000) 1.12
The impact of symptoms and impairments on overall health in US national health data. Med Care (2008) 1.11
What are cancer patients' preferences about treatment at the end of life, and who should start talking about it? A comparison with healthy people and medical staff. Support Care Cancer (2005) 1.10
Palliative chemotherapy or best supportive care? A prospective study explaining patients' treatment preference and choice. Br J Cancer (2003) 1.08
Outcomes and quality of life following breast cancer treatment in older women: when, why, how much, and what do women want? Health Qual Life Outcomes (2003) 1.08
Personal values and cancer treatment refusal. J Med Ethics (2000) 1.06
Integration of palliative care practices into the ongoing care of children with cancer: individualized care planning and coordination. Pediatr Clin North Am (2008) 1.03
Do patients with advanced breast cancer benefit from chemotherapy? Br J Cancer (1998) 1.01
Development of a patient registry to evaluate hospital admissions related to chemotherapy toxicity in a community cancer center. J Oncol Pract (2005) 0.98
Chemotherapy for solid tumours. Routine treatment not yet justified. BMJ (1995) 0.98
Patients' preferences for participation in treatment decision-making at the end of life: qualitative interviews with advanced cancer patients. PLoS One (2014) 0.97
Patient compliance with prolonged low-dose oral etoposide for small cell lung cancer. Br J Cancer (1993) 0.94
Treatment of androgen-independent, hormone-refractory prostate cancer with docetaxel in Japanese patients. Int J Clin Oncol (2005) 0.94
Intraoperative radiotherapy for early breast cancer: do health professionals choose convenience or risk? Radiat Oncol (2014) 0.92
Out-of-pocket expenses and treatment choice for men with prostate cancer. Urology (2012) 0.92
Listen to their answers! Response behaviour in the measurement of physical and role functioning. Qual Life Res (2008) 0.92
Use of chemotherapy at the end of life in a Portuguese oncology center. Support Care Cancer (2007) 0.91
Evaluating a patient's request for life-prolonging treatment: an ethical framework. J Med Ethics (2012) 0.91
Meta-analyses of randomised trials: when the whole is more than just the sum of the parts. Br J Cancer (1996) 0.90
Surgical preferences of patients at risk of hip fractures: hemiarthroplasty versus total hip arthroplasty. BMC Musculoskelet Disord (2011) 0.90
The impact of the perception of treatment choice on satisfaction with treatment, experienced chemotherapy burden and current quality of life. Br J Cancer (2004) 0.89
Pre-operative chemotherapy in early stage resectable non-small-cell lung cancer: a randomized feasibility study justifying a multicentre phase III trial. Br J Cancer (1999) 0.88
Beliefs and practices of patients with advanced cancer: implications for communication. Br J Cancer (2004) 0.88
Chemotherapy for advanced breast cancer: what influences oncologists' decision-making? Br J Cancer (2001) 0.88
Measuring the quality of later life. Philos Trans R Soc Lond B Biol Sci (1997) 0.88
Assessing patients' needs and preferences in the management of advanced colorectal cancer. Br J Cancer (1998) 0.84
[Communicative and ethical aspects of physician-patient relationship in extreme situations]. Wien Med Wochenschr (2015) 0.84
Therapy preferences in melanoma treatment--willingness to pay and preference of quality versus length of life of patients, physicians and healthy controls. PLoS One (2014) 0.83
Chemotherapy for cancer patients who present late. BMJ (2004) 0.83
Evaluating sequelae after head and neck cancer from the patient perspective with the help of the International Classification of Functioning, Disability and Health. Eur Arch Otorhinolaryngol (2008) 0.82
30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study. Lancet Oncol (2016) 0.81
Association of treatment and outcomes of doctor-shopping behavior in patients with hepatocellular carcinoma. Patient Prefer Adherence (2013) 0.81
The role of palliative chemotherapy in hospitalized patients. Curr Oncol (2014) 0.81
Australian clinicians and chemoprevention for women at high familial risk for breast cancer. Hered Cancer Clin Pract (2009) 0.81
Long-term quality of life after hepatic resection: health is not simply the absence of disease. World J Surg (2009) 0.81
What differences are detected by superiority trials or ruled out by noninferiority trials? A cross-sectional study on a random sample of two-hundred two-arms parallel group randomized clinical trials. BMC Med Res Methodol (2010) 0.81
Reconciling the principle of patient autonomy with the practice of informed consent: decision-making about prognostication in uveal melanoma. Health Expect (2010) 0.81
Combination or mild single agent chemotherapy for advanced breast cancer? CMF vs epirubicin measuring quality of life. Br J Cancer (1993) 0.80
Treatment priorities in oncology: do we want to live longer or better? Clinics (Sao Paulo) (2014) 0.79
The development of a decision aid to elicit treatment preferences for displaced femoral neck fractures. Indian J Orthop (2012) 0.79
Association of shared decision-making with type of breast cancer surgery: a cross-sectional study. BMC Health Serv Res (2010) 0.78
Do new cancer drugs offer good value for money? The perspectives of oncologists, health care policy makers, patients, and the general population. Patient Prefer Adherence (2015) 0.78
Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study. J Gynecol Oncol (2013) 0.78
Population-based utilities for upper extremity functions in the setting of tetraplegia. J Hand Surg Am (2009) 0.78
How should treatment decisions be made for incapacitated patients, and why? PLoS Med (2007) 0.78
Domiciliary chemotherapy with gemcitabine is safe and acceptable to advanced non-small-cell lung cancer patients: results of a feasibility study. Br J Cancer (2003) 0.77
New treatments for colon cancer. BMJ (2004) 0.77
Careful use of science to advance the debate on the UK Cancer Drugs Fund. JAMA (2014) 0.77
Ranked importance of outcomes of first-line versus repeated chemotherapy among ovarian cancer patients. Support Care Cancer (2009) 0.77
Patients' perspectives on palliative chemotherapy of colorectal and non--colorectal cancer: a prospective study in a chemotherapy- experienced population. BMC Cancer (2013) 0.77
Genes, dreams, and cancer. BMJ (1994) 0.76
Measuring quality of life: impact of chemotherapy for advanced colorectal cancer. Experience from two recent large phase III trials. Br J Cancer (1998) 0.76
Can we predict toxicity and efficacy in older patients with cancer? Older patients with colorectal cancer as an example. ESMO Open (2016) 0.75
The lung cancer paradox: time for action. Thorax (2002) 0.75
Quality and cost in the palliative care of cancer. Br J Cancer (1992) 0.75
Adjuvant treatment for breast cancer: the overview. BMJ (1992) 0.75
Doc, I don't want your poison. Oncologist (2012) 0.75
Completion of the audit cycle: standardised nurse-led information for patients. Postgrad Med J (2003) 0.75
Multidisciplinary team decision-making in cancer and the absent patient: a qualitative study. BMJ Open (2016) 0.75
Chemotherapy for solid tumours. BMJ (1995) 0.75
Palliative medicine. Postgrad Med J (1993) 0.75
Chemotherapy for advanced color. Please aim for accuracy rather than hard hitting headlines. BMJ (2001) 0.75
Attitudes to chemotherapy. BMJ (1990) 0.75
Who should pay for cancer drugs? J R Soc Med (2008) 0.75
Chemotherapy in advanced ovarian cancer. BMJ (1992) 0.75
How much survival benefit is necessary for breast cancer patients to opt for adjuvant chemotherapy? Results from a Chilean survey. Ecancermedicalscience (2014) 0.75
'Being there' for women with metastatic breast cancer: a pan-European patient survey. Br J Cancer (2013) 0.75
Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial. Br J Cancer (2016) 0.75
Information and participation preferences among cancer patients. Ann Intern Med (1980) 11.05
Who should measure quality of life, the doctor or the patient? Br J Cancer (1988) 6.32
Speech and survival: tradeoffs between quality and quantity of life in laryngeal cancer. N Engl J Med (1981) 4.34
Fallacy of the five-year survival in lung cancer. N Engl J Med (1978) 4.23
Disclosure of information to patients in medical care. Med Care (1981) 2.97
Talking about cancer: how much is too much? Br J Hosp Med (1987) 2.67
Preferences for treatment control among adults with cancer. Res Nurs Health (1988) 2.16
Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA (2001) 17.91
Mental health of hospital consultants: the effects of stress and satisfaction at work. Lancet (1996) 7.44
Who should measure quality of life, the doctor or the patient? Br J Cancer (1988) 6.32
General practitioner centred scheme for treatment of opiate dependent drug injectors in Glasgow. BMJ (1997) 4.75
Burnout and psychiatric disorder among cancer clinicians. Br J Cancer (1995) 4.47
Brain death in three neurosurgical units. Br Med J (Clin Res Ed) (1981) 4.34
Doctors' legal position in treating temporarily incompetent patients. BMJ (1995) 4.22
Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer. Lancet (1991) 4.09
Human chromosome 19 and related regions in mouse: conservative and lineage-specific evolution. Science (2001) 3.39
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res (1999) 3.24
Supporting problem drug users: improving methadone maintenance in general practice. Br J Gen Pract (1995) 3.15
Reflex sympathetic dystrophy: changing concepts and taxonomy. Pain (1995) 3.09
Benefits and harms of direct to consumer advertising: a systematic review. Qual Saf Health Care (2005) 2.61
Two-photon fluorescence microscopy of laurdan generalized polarization domains in model and natural membranes. Biophys J (1997) 2.56
Molecular epidemiology of tuberculosis in London 1995-7 showing low rate of active transmission. Thorax (2002) 2.53
A point mutation G----A in exon 12 of the porphobilinogen deaminase gene results in exon skipping and is responsible for acute intermittent porphyria. Nucleic Acids Res (1989) 2.39
Deprivation, psychological distress, and consultation length in general practice. Br J Gen Pract (2001) 2.23
Zim1, a maternally expressed mouse Kruppel-type zinc-finger gene located in proximal chromosome 7. Hum Mol Genet (1999) 2.20
Assessment of impact of information booklets on use of healthcare services: randomised controlled trial. BMJ (2001) 2.11
Community correlates of hospital use. Health Serv Res (1984) 2.06
The prognostic value of Ki67 immunostaining in non-Hodgkin's lymphoma. J Pathol (1988) 2.05
Trabeculectomy. Br J Ophthalmol (1972) 2.02
The ancestral gene for transcribed, low-copy repeats in the Prader-Willi/Angelman region encodes a large protein implicated in protein trafficking, which is deficient in mice with neuromuscular and spermiogenic abnormalities. Hum Mol Genet (1999) 2.02
An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. J Epidemiol Community Health (2003) 1.96
Illumination-dependent changes in the intrinsic fluorescence of bacteriorhodopsin. Biochemistry (1978) 1.95
A fellowship a year abroad: the 'pros' and 'cons'. Arch Emerg Med (1991) 1.94
Pneumocephalus associated with nasal continuous positive airway pressure in a patient with sleep apnea syndrome. Chest (1989) 1.94
Acute corneal hydrops in keratoconus. Ophthalmology (1994) 1.90
Prognostic factors for the progression of keratoconus. Ophthalmology (1994) 1.83
'Anti-bee' and 'pro-bird' changes during the evolution of hummingbird pollination in Penstemon flowers. J Evol Biol (2004) 1.81
Inhibition of growth of nonbasal planes in ice by fish antifreezes. Proc Natl Acad Sci U S A (1989) 1.80
Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol (2005) 1.80
Clinical signs of early osteoarthritis: reproducibility and relation to x ray changes in 541 women in the general population. Ann Rheum Dis (1991) 1.79
A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia (2011) 1.77
Quality-assessed reviews of health care interventions and the database of abstracts of reviews of effectiveness (DARE). NHS CRD Review, Dissemination, and Information Teams. Int J Technol Assess Health Care (1999) 1.75
The number and distribution of benign pigmented moles (melanocytic naevi) in a healthy British population. Br J Dermatol (1985) 1.75
A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol (1989) 1.72
Emotional support for cancer patients: what do patients really want? Br J Cancer (1996) 1.72
Inadequacy of iridium implant as sole radiation treatment for operable breast cancer. Eur J Cancer (1996) 1.70
What is the excess risk of infertility in women after genital chlamydia infection? A systematic review of the evidence. Sex Transm Infect (2007) 1.68
Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease. AIDS (1997) 1.68
Apparent increase in the prevalence of herpes simplex virus type 1 genital infections among women. Genitourin Med (1994) 1.64
Variations in the management and survival of women under 50 years with breast cancer in the South East Thames region. Br J Cancer (1996) 1.63
Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU Int (2010) 1.60
Pharmacokinetics of piperacillin following intravenous administration. J Antimicrob Chemother (1978) 1.57
Defining poor ovarian response during IVF cycles, in women aged <40 years, and its relationship with treatment outcome. Hum Reprod (2004) 1.57
Combined chemotherapy versus melphalan and prednisolone for treatment of myelomatosis. Lancet (1992) 1.52
Zooming in on the human-mouse comparative map: genome conservation re-examined on a high-resolution scale. Genome Res (1997) 1.52
Endotoxin immunity and the development of the systemic inflammatory response syndrome in critically ill children. Intensive Care Med (2006) 1.52
Randomised controlled trial of effect of Baby Check on use of health services in first 6 months of life. BMJ (1999) 1.51
The human homolog of a mouse-imprinted gene, Peg3, maps to a zinc finger gene-rich region of human chromosome 19q13.4. Genome Res (1997) 1.50
Advanced breast cancer: use of resources and cost implications. Br J Cancer (1993) 1.48
Stomatal vs. genome size in angiosperms: the somatic tail wagging the genomic dog? Ann Bot (2010) 1.47
Prediction of endocrine response in breast cancer by immunocytochemical detection of oestrogen receptor in fine-needle aspirates. Lancet (1987) 1.46
Estimation of the rate of unrecognized cross-contamination with mycobacterium tuberculosis in London microbiology laboratories. J Clin Microbiol (2002) 1.44
Reference data for bone mass, calciotropic hormones, and biochemical markers of bone remodeling in older (55-75) postmenopausal white and black women. J Bone Miner Res (1994) 1.42
CVID causing a granulomatous uveitis and optic disc neovascularisation mimicking sarcoid. Eye (Lond) (2008) 1.41
Apparent removal of graft-versus-leukaemia effect by the use of leucocyte-poor blood components in patients with acute myeloblastic leukaemia. Br J Haematol (1989) 1.40
Observation of B(0)(s)-->Psi(2S)Phi and measurement of the ratio of branching fractions Beta(B(0)(s)-->Psi(2S)Phi)/Beta(B(0)(s)-->J/PsiPhi). Phys Rev Lett (2006) 1.40
Female sterilisation: National Women's Hospital 1988-9. N Z Med J (1994) 1.40
The effectiveness and cost-effectiveness of prophylactic removal of wisdom teeth. Health Technol Assess (2000) 1.37
A systematic review of cancer waiting time audits. Qual Saf Health Care (2005) 1.35
Epidemiological assessment of the role of physical activity and fitness in development of cardiovascular disease. Am Heart J (1985) 1.35
Sedation for fibreoptic bronchoscopy. Thorax (1989) 1.35
Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol (1986) 1.34
Antibacterial activity, pharmacokinetics and efficacy of cefoxitin in patients with abdominal sepsis and other infections. J Antimicrob Chemother (1978) 1.34
PROforma: a general technology for clinical decision support systems. Comput Methods Programs Biomed (1997) 1.33
Trabeculectomy: long-term follow-up. Br J Ophthalmol (1977) 1.31
beta-catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumours. Int J Cancer (1999) 1.31
Vitamin d-stimulated intestinal calcium absorption may not involve calcium-binding protein directly. Nature (1976) 1.31
Cytomegalovirus retinitis in AIDS patients: influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival. AIDS (1996) 1.30
Precision top-quark mass measurement at CDF. Phys Rev Lett (2012) 1.30
Structure and function correlations at the imprinted mouse Snrpn locus. Mamm Genome (1998) 1.28
The role of recombination activating gene (RAG) reinduction in thymocyte development in vivo. J Exp Med (2001) 1.27
Discovery of a novel, paternally expressed ubiquitin-specific processing protease gene through comparative analysis of an imprinted region of mouse chromosome 7 and human chromosome 19q13.4. Genome Res (2000) 1.27
Phase I and pharmacokinetic study of rhizoxin. Cancer Res (1992) 1.26
Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer (1998) 1.26
Pathogenesis of subacute combined degeneration: a result of methyl group deficiency. Lancet (1981) 1.25
Effect of menstrual phase on surgical treatment of breast cancer. Lancet (1994) 1.24
Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene (2010) 1.24
Integrins in point contacts mediate cell spreading: factors that regulate integrin accumulation in point contacts vs. focal contacts. J Cell Biol (1993) 1.23
Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues. J Clin Endocrinol Metab (1988) 1.22
Extent of linkage disequilibrium in chicken. Cytogenet Genome Res (2007) 1.22
Measurement of the cross section for prompt isolated diphoton production using the full CDF run II data sample. Phys Rev Lett (2013) 1.22
Psychiatric disorder in patients with advanced breast cancer: prevalence and associated factors. Eur J Cancer (1993) 1.21
Airborne transmission of disease in hospitals. J R Soc Interface (2009) 1.20
Concordance between isolated cleft palate in mice and alterations within a region including the gene encoding the beta 3 subunit of the type A gamma-aminobutyric acid receptor. Proc Natl Acad Sci U S A (1993) 1.20
Is leaf dry matter content a better predictor of soil fertility than specific leaf area? Ann Bot (2011) 1.20
Methadone maintenance treatment. Glasgow has an innovative scheme for encouraging GPs to manage drug misusers. BMJ (1995) 1.18
Faecal lactoferrin--a novel test to differentiate between the irritable and inflamed bowel? Aliment Pharmacol Ther (2010) 1.18
The classification of ductal carcinoma in situ and its association with biological markers. Semin Diagn Pathol (1994) 1.18
Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res (1993) 1.18
Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol (2005) 1.17
Mechanisms of hypoxia-induced periodic breathing during sleep in humans. J Physiol (1983) 1.17
Peer advisers compared with specialist health professionals in delivering a training programme on self-management to people with diabetes: a randomized controlled trial. Diabet Med (2008) 1.17
A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol. Br J Cancer (2011) 1.17
A new mouse insertional mutation that causes sensorineural deafness and vestibular defects. Genetics (1999) 1.16